Brady Holmer

Are we just focused on calorie burn?

So yes, if

it's just focused on calorie burn.

Yes, the two are equivalent, but health is a lot more, as you know, than just burning calories.

People are focused on different health outcomes, like improving their fitness or improving their cardiovascular health, improving their diabetes risk.

So when you look at it from that perspective, it really changes the way that you think of, well, maybe it's not all just about metabolic equivalence.

Maybe it's about something different and we should be looking at the value of physical activity in different ways.

Yeah, and I do think that's important just for framing kind of when we start to talk about this study for framing our discussion today, because when people hear vigorous, especially, you know, as you usually talk about on your podcast, it's vigorous intensity is kind of this high intensity interval training.

But when it comes to the guidelines, vigorous is a lot less vigorous.

And people were probably familiar with zone two training.

I would just consider like when you hear vigorous in the context of this discussion or the physical activity guidelines, that's like zone two intensity or above basically.

So it includes high intensity interval training, but it also includes things are a little less intense than one might consider high intensity interval training to be.

Yeah, sure.

So this was by a group led by Stan Matakis is the first kind of author on it.

And importantly, they're the group behind a lot of these VILPA studies, Rhonda, that you've talked about a lot, the Vigorous Intermittent Lifestyle Physical Activity Studies.

So they authored this study and they mine data from the UK biobank.

That's just a huge... It's kind of similar to like the NHANES in the United States where...

just a cohort of a ton of individuals looked at for decades or more.

They have all this health data on them, objective data, subjective data.

So for this study, they focused on 73,000, more than 73,000 adults from the UK biobank who were aged 40 to 79.